Patent Information Users Group, Inc.

The International Society for Patent Information Professionals

↑

Search Community Job Board

Become a Member

Home
USPTO Biotechnology Chemical Pharmaceutical Customer Partnership Meeting Sep. 17, 2020, 9:00 AM - 5:00 PM ET [written description for antibodies; 101 & pharma patents; patent sequence searching, etc.]

Home
USPTO Biotechnology Chemical Pharmaceutical Customer Partnership Meeting Sep. 17, 2020, 9:00 AM - 5:00 PM ET [written description for antibodies; 101 & pharma patents; patent sequence searching, etc.]

Back to topics

USPTO Biotechnology Chemical Pharmaceutical Customer Partnership Meeting Sep. 17, 2020, 9:00 AM - 5:00 PM ET [written description for antibodies; 101 & pharma patents; patent sequence searching, etc.]

Show oldest replies on top

Subscribe to topic

14 Sep 2020 4:37 PM

Message # 9235154

Anonymous member

USPTO’s next Biotechnology, Chemical, and Pharmaceutical Customer Partnership (BCP) Meeting is scheduled for September 17, 2020 9:00 AM: 5:00 PM ET and will be held online.

BCP meetings are part of a long-standing partnership between the USPTO and its valued stakeholders that works to improve the quality the agency’s products and services.

The BCP Agenda is available for your review.

The selected items from the Agenda is listed below:

Time	Title	Presenter(s)
9:10–9:50 a.m.	Antibodies and the written description requirement of 35 U.S.C. 112(a)	Daniel Kolker SPE, TC1600, USPTO [See Note 1]
9:50 –10:20 a.m	Written description for antibodies and other biologics	Carla Mouta-Bellum, Ph.D., J.D. Partner, Arrigo, Lee, Guttman & Mouta-Bellum
1:00 –2:30 p.m.	Revised patent subject matter eligibility guidance	Zachariah Lucas QAS, TC1600, USPTO
2:30 –3:20 p.m.	The impact of 101 on pharmaceutical patents	MaCharri R. Vorndran-Jones, J.D. Assistant General Patent Counsel James P. Leeds, J.D. Assistant General Patent Counsel Eli Lilly and Company
4:20 –4:50 p.m.	Basic introduction to searching patent sequence data using BLAST	Peter S. Cooper, Ph.D. Staff Scientist User services, National Center for Biotechnology Information, NLM/NIH
4:20 –4:50 p.m.	LensPatseq: An open facility for biotech patent professionals	Osmat A. Jefferson, Ph.D., Director, Lens Product Development, Cambia, Professor of Science, Technology, and Law, Queensland University of Technology

Presentations may start later or earlier than scheduled depending on how long the previous talks on the agenda will be.

To register, please email USPTOBCP1600@USPTO.GOV by Tuesday, September 15. Make sure to include the following information:

Subject: BCP RSVP
Your name, title, and organization
Contact information (e-mail, phone, etc.)

Webex link to join

https://www.uspto.gov/about-us/events/attend-biotechnology-chemical-and-pharmaceutical-partnership-meeting-0

Note 1. Documents and presentations related written description of antibodies:

USPTO Memorandum “Clarification of Written Description Guidance For Claims Drawn to Antibodies and Status of 2008 Training Materials", February 22, 2018, 2p.
USPTO Antibody Decisions and Their Compliance with the Written Description Requirement. PowerPoint of the CBT [27 p, 2015]
Feng, L., Lewis, S.D. (Finnegan) 2018. Patenting Antibodies: Written Description Concerns in Antibody Patents. IPWatchdog.com Blog. May 18, 2018.
Yadav-Ranjan, K., 2020. Patenting Antibodies: A Complication in Written Description Jurisprudence. DePaul J. Health Care L. v. 21 No.3. Article 2 (24 p.)

Update 9/14/2020: A title of Cambia talk has been changed by an author to better reflect the content.

Last modified: 16 Sep 2020 5:29 PM | Anonymous member

In this Section:

Mailing Address:
40 E. Main St., #1438
Newark, DE 19711

Phone: +1 (302) 660-3275
Fax: +1 (302) 660-3276
Email: PIUGinfo@piug.org

Webmaster: webmaster@piug.org

Notice on use of PIUG name and logo:

No one may use the PIUG name or logo for any promotional or commercial purpose or any other purpose without the prior written consent of the PIUG Board of Directors.